Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque Psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Kim A. Papp, James G. Krueger, Steven R. Feldman, Richard G. Langley, Diamant Thaci, Hideshi Torii, Stephen Tyring, Robert Wolk, Annie Gardner, Charles Mebus, Huaming Tan, Yingchun Luo, Pankaj Gupta, Lotus Mallbris, Svitlana Tatulych*

*Korrespondierende/r Autor/-in für diese Arbeit
40 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque Psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medizin & Biologie